January 25, 2015 5:53 AM ET

Healthcare Providers and Services

Company Overview of Profarma Distribuidora de Produtos Farmacêuticos S.A.

Company Overview

Profarma Distribuidora de Produtos Farmacêuticos S.A. is engaged in the distribution, wholesale, and retail of pharmaceutical and hospital products in Brazil. The company operates through Pharmaceutical Distribution, Hospital & Special Medications, and Retail segments. It provides medicines, personal care, beauty, and dermatological products; and toiletries, vaccines, prostheses, and hormones in the South, Southeast, Northeast, and Center-West regions of Brazil through 12 distribution centers. The company also operates approximately 140 stores in the state of Rio de Janeiro. In addition, it provides information technology, cargo and transportation planning and control, and sales promotion an...

Avenida das Américas

nº 500, Bloco 12

sala 106

Grupo 205 à 208, Barra da Tijuca

Rio de Janeiro, RJ 22640-100

Brazil

Founded in 1961

Phone:

55 21 4009 0276

Fax:

55 21 2494 7333

Key Executives for Profarma Distribuidora de Produtos Farmacêuticos S.A.

Profarma Distribuidora de Produtos Farmacêuticos S.A. does not have any Key Executives recorded.

Profarma Distribuidora de Produtos Farmacêuticos S.A. Key Developments

Profarma Distribuidora de Produtos Farmacêuticos S.A. Announces Consolidated Earnings Results for the Third Quarter and Nine Months and Parent Earnings Results for the Third Quarter Ended September 30, 2014

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced consolidated earnings results for the third quarter and nine months and parent earnings results for the third quarter ended September 30, 2014. For the quarter, the consolidated company reported net revenues were BRL 855.2 million against BRL 871.4 million a year ago. EBIT were BRL 13.3 million against BRL 27 million a year ago. EBITDA were BRL 19.2 million against BRL 29.1 million a year ago. Net loss was BRL 20.6 million against BRL 5.4 million a year ago. Net loss per batch of one thousand shares was BRL 495 against income of BRL 159 a year ago. Net debt was BRL 211.3 million against BRL 432.8 million a year ago. Adjusted EBITDA were BRL 19.2 million against BRL 29.1 million a year ago. Adjusted net income was BRL 0.7 million against BRL 7.6 million a year ago. Proforma operational net revenues were BRL 1,029.0 million against BRL 949.3 million a year ago. Proforma net loss was BRL 22.2 million against BRL 7.5 million a year ago. Proforma adjusted net income were BRL 2.4 million against loss of BRL 5.3 million a year ago. In the third quarter of 2014, capital expenditures totaled BRL 5.7 million, BRL 4.8 million of which corresponding to Drogasmil /Farmalife, mainly allocated to facilities, machinery, equipment (BRL 2.5 million) and information technology (IT), BRL 0.9 million. Cash flow used in operating activities was BRL 27.0 million against BRL 4.5 million a year ago. Operating loss was BRL 23.381 million against income of BRL 6.938 million a year ago. Additions to fixed assets were BRL 5.581 million against BRL 0.423 million a year ago. Additions to intangible assets were BRL 1.026 million against BRL 0.135 million a year ago. For the nine months, the consolidated company reported net revenues were BRL 878.6 million against BRL 871.4 million a year ago. EBIT were BRL 13.3 million against BRL 27 million a year ago. EBIT were BRL 19.2 million against BRL 29.1 million a year ago. Net loss was BRL 20.6 million against BRL 5.4 million a year ago. Net debt was BRL 211.3 million against BRL 432.8 million a year ago. For the quarter, the parent company reported net revenues were BRL 831.01 million against BRL 779.52 million a year ago. Operating loss was BRL 23.34 million against income of BRL 7.11 million a year ago. Net loss was BRL 20.57 million against income of BRL 5.37 million a year ago. Net loss per batch of one thousand shares was BRL 495 against income of BRL 159 a year ago. Cash used in operating activities was BRL 20.49 million against cash from operating activities of BRL 19.04 million a year ago. Additions to fixed assets were BRL 0.900 million against BRL 0.418 million a year ago. Additions to intangible assets were BRL 0.002 million against BRL 0.112 million a year ago.

Profarma Distribuidora de Produtos Farmacêuticos S.A.(BOVESPA:PFRM3) dropped from Brazil Small Cap Index

Profarma Distribuidora de Produtos Farmacêuticos S.A. will be removed from the Brazil Small Cap Index.

Profarma Distribuidora de Produtos Farmacêuticos S.A. Announces Unaudited Consolidated and Parent Earnings Results for the Second Quarter Ended June 30, 2014; Announces Write of Fixed Assets/Intangibles for the Second Quarter of 2014

Profarma Distribuidora de Produtos Farmacêuticos S.A. announced unaudited consolidated and parent earnings results for the second quarter ended June 30, 2014. For the quarter, on consolidated basis, the company reported gross operating revenue was BRL 1,009,202,000 compared to BRL 1,016,927,000 for the same period a year ago. Net operating revenue was BRL 878,613,000 compared to BRL 880,046,000 for the same period a year ago. Operating income prior to financial results was BRL 6,241,000 compared to BRL 24,635,000 for the same period a year ago. Operating income was BRL 1,812,000 compared to BRL 13,127,000 for the same period a year ago. Net income before minority interests was BRL 2,141,000 compared to BRL 11,871,000 for the same period a year ago. Net income for the quarter was BRL 2,141,000 compared to BRL 12,640,000 for the same period a year ago. Net income per batch of 1,000 shares was BRL 52 compared to BRL 377 for the same period a year ago. Cash used in operating activities was BRL 11,898,000 compared to BRL 31,610,000 for the same period a year ago. Additions to fixed assets were BRL 4,064,000 compared to BRL 1,469,000 for the same period a year ago. Additions to intangible assets were BRL 831,000 compared to BRL 196,000 for the same period a year ago. EBITDA was BRL 20.4 million compared to BRL 33.1 million for the same period a year ago. Net debt was BRL 167.1 million compared to BRL 359.4 million at the same period a year ago. Adjusted net income was BRL 4.4 million compared to BRL 19.0 million for the same period a year ago. The consolidated data show a decrease in net income reflecting a rise of BRL 8.7 million in net financial expense directly connected with the company's higher debt, mainly due to the acquisitions of the Drogasmil/Farmalife and Tamoio drugstore chains in 2013. Net income was impacted by the 6% lower number of business days and the 22.2% lower price increase in second quarter of 2014. At their usual levels, these events would have impacted net income positively by about BRL 12.3 million. For the quarter, on parent company basis, the company reported gross operating revenue was BRL 877,280,000 compared to BRL 906,405,000 for the same period a year ago. Net operating revenue was BRL 760,765,000 compared to BRL 782,792,000 for the same period a year ago. Operating income prior to financial results was BRL 1,122,000 compared to BRL 23,048,000 for the same period a year ago. Operating income was BRL 2,573,000 compared to BRL 13,828,000 for the same period a year ago. Net income before minority interests was BRL 2,141,000 compared to BRL 12,640,000 for the same period a year ago. Net income for the quarter was BRL 2,141,000 compared to BRL 12,640,000 for the same period a year ago. Net income per batch of one thousand shares was BRL 52 compared to BRL 377 for the same period a year ago. Cash used in operating activities was BRL 12,253,000 compared to BRL 18,629,000 for the same period a year ago. Additions to fixed assets were BRL 1,116,000 compared to BRL 1,356,000 for the same period a year ago. Additions to intangible assets were BRL 136,000 compared to nil for the same period a year ago. Adjusted net loss was BRL 1.3 million compared to adjusted net income of BRL 2.1 million for the same period a year ago. On consolidated basis, for the quarter the company reported, write of fixed assets/intangible of BRL 113,000 compared to BRL 46,000 for the same period a year ago and on parent company basis write of fixed assets/intangible was BRL 98,000 compared to BRL 2,000 for the same period a year ago.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 20, 2014
Arp Med SA
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Profarma Distribuidora de Produtos Farmacêuticos S.A., please visit www.profarma.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.